Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK41959 in Patients With MTAP Deletion Locally Advanced or Metastatic Solid Tumors

NCT06968572 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT06968572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06968572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK41959 in Patients With MTAP Deletion Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 11, 2025
Completion date
May 8, 2028
Enrollment
245 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors